Mass Tort brief
Hernia Mesh Verdicts and Duty-to-Innovate Limits
A landmark federal bellwether verdict hits Medtronic while California limits legal liability over drug release timing.
Mass Tort
An $88 million bellwether verdict forces Medtronic onto the defensive — establishing expensive precedent across 2,400 pending hernia mesh claims.
BackgroundBellwether trials test representative claims in consolidated multidistrict litigation to establish settlement benchmarks. Thousands of similar personal injury suits against medical device makers depend on these test verdicts.
- The jury found Covidien failed to warn surgeons that the protective mesh coating dissolved in 7 days rather than 30, leading to severe organ damage.
- The award includes $77 million in compensatory damages to the primary plaintiff for severe bowel injuries requiring corrective surgeries.
- Medtronic pledged to appeal the ruling as over 2,400 claims remain consolidated in Massachusetts federal court under MDL 3029.
Mass Tort
California's highest court closed the door on duty-to-innovate claims — shielding manufacturers from liability over the timing of product upgrades.
BackgroundPlaintiffs alleged Gilead delayed developing safer HIV medications to maximize profits on older treatments before patent expiration. Lower courts struggled with whether commercial product rollout schedules could create general negligence liability.
- Justices rejected arguments that would establish hindsight liability over commercial product release timing, protecting corporate product lifecycles.
- The decision dismisses 24,000 state law claims asserting Gilead caused preventable kidney and bone injuries by delaying safer TAF-based drugs.
- Legal analysts note the ruling prevents expanding product liability into commercial software and device update schedules across healthcare and technology.
Mass Tort
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
